Analysts forecast that Genomic Health, Inc. (NASDAQ:GHDX) will announce $0.31 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Genomic Health’s earnings. The lowest EPS estimate is $0.30 and the highest is $0.33. Genomic Health posted earnings of $0.08 per share in the same quarter last year, which suggests a positive year-over-year growth rate of 287.5%. The company is expected to issue its next earnings report on Thursday, March 14th.

On average, analysts expect that Genomic Health will report full-year earnings of $1.06 per share for the current fiscal year, with EPS estimates ranging from $1.04 to $1.07. For the next fiscal year, analysts expect that the company will post earnings of $1.23 per share, with EPS estimates ranging from $1.04 to $1.55. Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Genomic Health.

Genomic Health (NASDAQ:GHDX) last released its quarterly earnings results on Tuesday, November 6th. The medical research company reported $0.35 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.07 by $0.28. Genomic Health had a net margin of 4.95% and a return on equity of 14.05%. The business had revenue of $101.30 million for the quarter, compared to the consensus estimate of $94.27 million. During the same period last year, the firm earned ($0.06) earnings per share. The company’s quarterly revenue was up 23.2% on a year-over-year basis.

Several research firms have weighed in on GHDX. Zacks Investment Research downgraded shares of Genomic Health from a “buy” rating to a “hold” rating in a research report on Thursday, August 30th. BidaskClub downgraded shares of Genomic Health from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 4th. Canaccord Genuity reiterated a “buy” rating and issued a $82.00 price target (up from $70.00) on shares of Genomic Health in a research report on Wednesday, November 7th. Finally, Raymond James began coverage on shares of Genomic Health in a research report on Tuesday, October 23rd. They issued a “market perform” rating on the stock. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $48.33.

GHDX opened at $72.90 on Wednesday. Genomic Health has a 1-year low of $26.54 and a 1-year high of $92.18. The company has a market capitalization of $2.73 billion, a price-to-earnings ratio of 92.07 and a beta of 0.40.

In other news, insider Steven Shak sold 5,500 shares of the firm’s stock in a transaction on Monday, September 10th. The shares were sold at an average price of $63.05, for a total transaction of $346,775.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, COO Frederic Pla sold 1,500 shares of the firm’s stock in a transaction on Monday, October 8th. The shares were sold at an average price of $65.43, for a total transaction of $98,145.00. The disclosure for this sale can be found here. Insiders have sold a total of 1,635,985 shares of company stock worth $126,469,701 over the last 90 days. Insiders own 45.80% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Clearbridge Investments LLC purchased a new position in Genomic Health during the third quarter valued at $12,880,000. Vanguard Group Inc. grew its stake in Genomic Health by 18.6% during the third quarter. Vanguard Group Inc. now owns 2,151,932 shares of the medical research company’s stock valued at $151,109,000 after acquiring an additional 337,664 shares in the last quarter. Kepos Capital LP purchased a new position in Genomic Health during the third quarter valued at $1,864,000. Nordea Investment Management AB grew its stake in Genomic Health by 17.5% during the third quarter. Nordea Investment Management AB now owns 79,128 shares of the medical research company’s stock valued at $5,557,000 after acquiring an additional 11,776 shares in the last quarter. Finally, TIAA CREF Investment Management LLC grew its stake in Genomic Health by 38.0% during the third quarter. TIAA CREF Investment Management LLC now owns 242,839 shares of the medical research company’s stock valued at $17,052,000 after acquiring an additional 66,873 shares in the last quarter. 89.21% of the stock is owned by institutional investors.

Genomic Health Company Profile

Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.

Recommended Story: Insider Trading

Get a free copy of the Zacks research report on Genomic Health (GHDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.